Clinical Trials
32 trialsAssociation of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
Memorial Sloan Kettering Cancer Center
Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Ipilimumab and Nivolumab in Leptomeningeal Metastases
Massachusetts General Hospital
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
Alaunos Therapeutics
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Rigshospitalet, Denmark
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
National Institutes of Health Clinical Center (CC)
CheckMate548
Bristol-Myers Squibb
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
CheckMate 143
Bristol-Myers Squibb
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
University of Pittsburgh
GMCI
Candel Therapeutics, Inc.
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
University of California, San Francisco
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
NIVOGLIO
Gustave Roussy, Cancer Campus, Grand Paris
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
National Institutes of Health Clinical Center (CC)
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
REVOLUMAB
Assistance Publique - Hôpitaux de Paris
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Novo Nordisk A/S
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
Saint John's Cancer Institute
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CheckMate 498
Bristol-Myers Squibb
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
H. Lee Moffitt Cancer Center and Research Institute
FPA008-003
Five Prime Therapeutics, Inc.
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AVERT
Duke University
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Celldex Therapeutics
Neo-nivo
Clinica Universidad de Navarra, Universidad de Navarra